ABSTRACT
This article describes a process of fabricating highly porous paper from cellulosic fibers and carbon black (CB) with tunable conductivity. By embossing such paper, its porosity decreases while its conductivity increases. Tuning the porosity of composite paper alters the magnitude and trend of conductivity over a spectrum of concentrations of conductive particles. The largest increase in conductivity from 8.38 × 10-6 to 2.5 × 10-3 S/m by a factor of â¼300 occurred at a percolation threshold of 3.8 wt % (or 0.36 vol %) with the composite paper plastically compressed by 410 MPa, which caused a decrease of porosity from 88% to 42% on average. Our composite paper showed stable piezoresistive responses within a broad pressure range from 1 kPa up to 5.5 MPa for 800 cycles. The piezoresistive sensitivities of the composite paper were dependent on concentration and decreased with pressure. Composite paper with 7.5 wt % CB had sensitivities of -0.514 kPa-1 over applied pressures ranging from 1 to 50 kPa and -0.215 kPa-1 from 1 to 250 kPa. This piezoresistive paper with embossed patterns enabled touch sensing and detection of damage from darts and punches. Understanding the percolation behavior of three-phase composites (cellulosic fibers/conductive particles/air) and their response to damage, pressure, and processing conditions has the potential to enable scalable applications in prosthetics and robotics, haptic feedback, or structural health monitoring on expansive surfaces of buildings and vehicles.
ABSTRACT
[This corrects the article DOI: 10.1371/journal.pone.0174166.].
ABSTRACT
OBJECTIVE: High sensitivity plasma cardiac troponin-I (cTnI) is emerging as a strong predictor of cardiac events in a variety of settings. We have explored its utility in patients with myotonic dystrophy type 1 (DM1). METHODS: 117 patients with DM1 were recruited from routine outpatient clinics across three health boards. A single measurement of cTnI was made using the ARCHITECT STAT Troponin I assay. Demographic, ECG, echocardiographic and other clinical data were obtained from electronic medical records. Follow up was for a mean of 23 months. RESULTS: Fifty five females and 62 males (mean age 47.7 years) were included. Complete data were available for ECG in 107, echocardiography in 53. Muscle Impairment Rating Scale score was recorded for all patients. A highly significant excess (p = 0.0007) of DM1 patients presented with cTnI levels greater than the 99th centile of the range usually observed in the general population (9 patients; 7.6%). Three patients with elevated troponin were found to have left ventricular systolic dysfunction (LVSD), compared with four of those with normal range cTnI (33.3% versus 3.7%; p = 0.001). Sixty two patients had a cTnI level < 5ng/L, of whom only one had documented evidence of LVSD. Elevated cTnI was not predictive of severe conduction abnormalities on ECG, or presence of a cardiac device, nor did cTnI level correlate with muscle strength expressed by Muscle Impairment Rating Scale score. CONCLUSIONS: Plasma cTnI is highly elevated in some ambulatory patients with DM1 and shows promise as a tool to aid cardiac risk stratification, possibly by detecting myocardial involvement. Further studies with larger patient numbers are warranted to assess its utility in this setting.
